BR112020006976A2 - anticorpos monoclonais anti-trkb e métodos de uso - Google Patents
anticorpos monoclonais anti-trkb e métodos de uso Download PDFInfo
- Publication number
- BR112020006976A2 BR112020006976A2 BR112020006976-0A BR112020006976A BR112020006976A2 BR 112020006976 A2 BR112020006976 A2 BR 112020006976A2 BR 112020006976 A BR112020006976 A BR 112020006976A BR 112020006976 A2 BR112020006976 A2 BR 112020006976A2
- Authority
- BR
- Brazil
- Prior art keywords
- trkb
- antibody
- antigen
- binding fragment
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592657P | 2017-11-30 | 2017-11-30 | |
| US62/592,657 | 2017-11-30 | ||
| PCT/US2018/062863 WO2019108662A1 (en) | 2017-11-30 | 2018-11-28 | Anti-trkb monoclonal antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020006976A2 true BR112020006976A2 (pt) | 2020-10-13 |
Family
ID=64665125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020006976-0A BR112020006976A2 (pt) | 2017-11-30 | 2018-11-28 | anticorpos monoclonais anti-trkb e métodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11066474B2 (https=) |
| EP (1) | EP3717514A1 (https=) |
| JP (2) | JP7438937B2 (https=) |
| KR (1) | KR20200090779A (https=) |
| CN (2) | CN111372949B (https=) |
| AU (3) | AU2018375340B2 (https=) |
| BR (1) | BR112020006976A2 (https=) |
| CA (1) | CA3083452A1 (https=) |
| CL (3) | CL2020000855A1 (https=) |
| CO (1) | CO2020004075A2 (https=) |
| EA (1) | EA202090966A1 (https=) |
| IL (1) | IL273538B2 (https=) |
| MA (1) | MA51207A (https=) |
| MX (3) | MX2020003550A (https=) |
| MY (1) | MY203247A (https=) |
| PH (1) | PH12020550409A1 (https=) |
| SG (1) | SG11202002665UA (https=) |
| WO (1) | WO2019108662A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
| IL310006A (en) * | 2017-11-30 | 2024-03-01 | Regeneron Pharma | Non-human animals containing a humanized TRKB locus |
| JP7524158B2 (ja) * | 2019-03-04 | 2024-07-29 | 公益財団法人東京都医学総合研究所 | Ｔｒｋ断片をコードする核酸構築物、及びその利用 |
| US12559560B2 (en) * | 2020-01-30 | 2026-02-24 | Fred Hutchinson Cancer Center | Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms |
| WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
| TW202342494A (zh) | 2022-03-30 | 2023-11-01 | 日商肽夢想股份有限公司 | 具有TrkB結合活性之肽複合物 |
| CN120665203B (zh) * | 2025-06-18 | 2026-03-27 | 广东优赛生物医药科技有限公司 | 一种药物组合物及其在治疗中枢性肥胖中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US6225282B1 (en) | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2006133164A2 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| EP1988923A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
| EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| WO2008058127A2 (en) | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
| CA2672750A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | Trkb agonists for treating autoimmune disorders |
| WO2009048605A1 (en) | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| CA2712298C (en) | 2008-01-17 | 2015-11-24 | Irm Llc | Improved anti-trkb antibodies |
| WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| WO2011103667A1 (en) | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
| GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
| US10080745B2 (en) | 2013-11-25 | 2018-09-25 | The Regents Of The University Of California Santa Cruz | Piericidin bacterial inhibitors |
| ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| CA2993645A1 (en) | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
| JP2019517787A (ja) * | 2016-05-03 | 2019-06-27 | ザ スクリプス リサーチ インスティテュート | 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体 |
| US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| EP4095161A1 (en) * | 2017-03-15 | 2022-11-30 | Tsinghua University | Novel anti-trkb antibodies |
| WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
-
2018
- 2018-11-28 WO PCT/US2018/062863 patent/WO2019108662A1/en not_active Ceased
- 2018-11-28 AU AU2018375340A patent/AU2018375340B2/en active Active
- 2018-11-28 CA CA3083452A patent/CA3083452A1/en active Pending
- 2018-11-28 MY MYPI2020001663A patent/MY203247A/en unknown
- 2018-11-28 MX MX2020003550A patent/MX2020003550A/es unknown
- 2018-11-28 SG SG11202002665UA patent/SG11202002665UA/en unknown
- 2018-11-28 MA MA051207A patent/MA51207A/fr unknown
- 2018-11-28 CN CN201880069154.2A patent/CN111372949B/zh active Active
- 2018-11-28 BR BR112020006976-0A patent/BR112020006976A2/pt unknown
- 2018-11-28 PH PH1/2020/550409A patent/PH12020550409A1/en unknown
- 2018-11-28 CN CN202511361457.XA patent/CN121181700A/zh active Pending
- 2018-11-28 EA EA202090966A patent/EA202090966A1/ru unknown
- 2018-11-28 IL IL273538A patent/IL273538B2/en unknown
- 2018-11-28 EP EP18819293.4A patent/EP3717514A1/en active Pending
- 2018-11-28 JP JP2020517858A patent/JP7438937B2/ja active Active
- 2018-11-28 US US16/202,881 patent/US11066474B2/en active Active
- 2018-11-28 KR KR1020207014791A patent/KR20200090779A/ko active Pending
-
2020
- 2020-03-31 CL CL2020000855A patent/CL2020000855A1/es unknown
- 2020-06-03 CO CONC2020/0004075A patent/CO2020004075A2/es unknown
- 2020-07-13 MX MX2025001445A patent/MX2025001445A/es unknown
- 2020-07-13 MX MX2025001444A patent/MX2025001444A/es unknown
-
2021
- 2021-06-09 US US17/342,749 patent/US12037401B2/en active Active
-
2023
- 2023-11-09 JP JP2023191236A patent/JP2024016204A/ja active Pending
-
2024
- 2024-06-07 US US18/737,782 patent/US20240309100A1/en active Pending
- 2024-08-30 CL CL2024002612A patent/CL2024002612A1/es unknown
- 2024-08-30 CL CL2024002614A patent/CL2024002614A1/es unknown
-
2026
- 2026-01-28 AU AU2026200583A patent/AU2026200583A1/en active Pending
- 2026-01-28 AU AU2026200616A patent/AU2026200616A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7589200B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| US12037401B2 (en) | Anti-TrkB monoclonal antibodies and methods of use | |
| CN102933602B (zh) | 人gdf8的抗体 | |
| CN104768974B (zh) | GFRα3的人抗体及其使用方法 | |
| BR112015016312B1 (pt) | Anticorpos anti-pdgfr-beta, seus usos e composição farmacêutica | |
| RS62454B1 (sr) | Anti-asic1 antitela i njihove upotrebe | |
| EA044580B1 (ru) | Моноклональные анти-trkb антитела и способы их применения | |
| BR122023008586B1 (pt) | Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à activina a, composição farmacêutica e uso do mesmo | |
| NZ716854B2 (en) | Anti-activin a antibodies and uses thereof | |
| BR112015003110B1 (pt) | Anticorpo isolado monoclonal ou um seu fragmento de ligação a antígeno, molécula de ácido nucleico isolada, vetor de expressão, método para produzir anticorpo ou seu fragmento de ligação a antígeno, uso do anticorpo isolado ou de seu fragmento de ligação a antígeno, composição farmacêutica, e, uso da composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |